<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Ocul Pharmacol Ther</journal-id>
<journal-id journal-id-type="iso-abbrev">J Ocul Pharmacol Ther</journal-id>
<journal-id journal-id-type="publisher-id">jop</journal-id>
<journal-title-group>
<journal-title>Journal of Ocular Pharmacology and Therapeutics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1080-7683</issn>
<issn pub-type="epub">1557-7732</issn>
<publisher>
<publisher-name>Mary Ann Liebert, Inc.</publisher-name>
<publisher-loc>140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28820649</article-id>
<article-id pub-id-type="pmc">5963639</article-id>
<article-id pub-id-type="publisher-id">10.1089/jop.2017.0041</article-id>
<article-id pub-id-type="doi">10.1089/jop.2017.0041</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Volume 1: Glaucoma IOP, Neuroprotection and Devices</subject>
<subj-group>
<subject>Original Articles</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Targets of Neuroprotection in Glaucoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Shaoqing</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stankowska</surname>
<given-names>Dorota L.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ellis</surname>
<given-names>Dorette Z.</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krishnamoorthy</surname>
<given-names>Raghu R.</given-names>
</name>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yorio</surname>
<given-names>Thomas</given-names>
</name>
</contrib>
<aff id="aff1">North Texas Eye Research Institute, <institution>University of North Texas Health Science Center</institution>, Fort Worth, Texas.</aff>
</contrib-group>
<author-notes>
<corresp>
<addr-line>Address correspondence to:</addr-line>
<addr-line>
<italic>Dr. Thomas Yorio</italic>
</addr-line>
<addr-line>
<italic>North Texas Eye Research Institute</italic>
</addr-line>
<institution>
<italic>University of North Texas Health Science Center</italic>
</institution>
<addr-line>
<italic>3500 Camp Bowie Boulevard</italic>
</addr-line>
<addr-line>
<italic>Fort Worth, TX 76107</italic>
</addr-line>
<italic>E-mail:</italic>
<email xlink:href="mailto:thomas.yorio@unthsc.edu">thomas.yorio@unthsc.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="ppub">
<day>01</day>
<month>3</month>
<year>2018</year>
<!--string-date: Jan/Feb/March 2018-->
</pub-date>
<pub-date pub-type="epub">
<day>01</day>
<month>3</month>
<year>2018</year>
</pub-date>
<volume>34</volume>
<issue>1-2</issue>
<fpage>85</fpage>
<lpage>106</lpage>
<history>
<date date-type="received">
<day>03</day>
<month>4</month>
<year>2017</year>
<!--string-date: Received: April 3, 2017-->
</date>
<date date-type="accepted">
<day>08</day>
<month>6</month>
<year>2017</year>
<!--string-date: Accepted: June 8, 2017-->
</date>
</history>
<permissions>
<copyright-statement>Copyright 2018, Mary Ann Liebert, Inc.</copyright-statement>
<copyright-year>2018</copyright-year>
</permissions>
<self-uri content-type="pdf" xlink:href="jop.2017.0041.pdf" xlink:type="simple"></self-uri>
<abstract>
<title>Abstract</title>
<p>Progressive neurodegeneration of the optic nerve and the loss of retinal ganglion cells is a hallmark of glaucoma, the leading cause of irreversible blindness worldwide, with primary open-angle glaucoma (POAG) being the most frequent form of glaucoma in the Western world. While some genetic mutations have been identified for some glaucomas, those associated with POAG are limited and for most POAG patients, the etiology is still unclear. Unfortunately, treatment of this neurodegenerative disease and other retinal degenerative diseases is lacking. For POAG, most of the treatments focus on reducing aqueous humor formation, enhancing uveoscleral or conventional outflow, or lowering intraocular pressure through surgical means. These efforts, in some cases, do not always lead to a prevention of vision loss and therefore other strategies are needed to reduce or reverse the progressive neurodegeneration. In this review, we will highlight some of the ocular pharmacological approaches that are being tested to reduce neurodegeneration and provide some form of neuroprotection.</p>
</abstract>
<kwd-group kwd-group-type="author">
<title><bold>Keywords:</bold>â€‚</title>
<kwd>glaucoma</kwd>
<kwd>drug targets</kwd>
<kwd>neuroprotection</kwd>
</kwd-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="2"></table-count>
<ref-count count="281"></ref-count>
<page-count count="22"></page-count>
</counts>
</article-meta>
</front>
</article>
</pmc-articleset>